These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30518629)

  • 21. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
    Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
    Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.
    Giuriato S; Faumont N; Bousquet E; Foisseau M; Bibonne A; Moreau M; Al Saati T; Felsher DW; Delsol G; Meggetto F
    Cancer Biol Ther; 2007 Aug; 6(8):1318-23. PubMed ID: 17660712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LTK fusions: A new target emerges in non-small cell lung cancer.
    Cooper AJ; Sequist LV; Johnson TW; Lin JJ
    Cancer Cell; 2022 Jan; 40(1):23-25. PubMed ID: 35016028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
    Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
    PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
    J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions.
    Devereaux KA; Fitzpatrick MB; Hartinger S; Jones C; Kunder CA; Longacre TA
    Am J Surg Pathol; 2020 Jul; 44(7):970-981. PubMed ID: 32271187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
    van der Krogt JA; Bempt MV; Ferreiro JF; Mentens N; Jacobs K; Pluys U; Doms K; Geerdens E; Uyttebroeck A; Pierre P; Michaux L; Devos T; Vandenberghe P; Tousseyn T; Cools J; Wlodarska I
    Haematologica; 2017 Sep; 102(9):1605-1616. PubMed ID: 28659337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
    Parker BM; Parker JV; Lymperopoulos A; Konda V
    J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity?
    Olsen TK; Panagopoulos I; Meling TR; Micci F; Gorunova L; Thorsen J; Due-Tønnessen B; Scheie D; Lund-Iversen M; Krossnes B; Saxhaug C; Heim S; Brandal P
    Neuro Oncol; 2015 Oct; 17(10):1365-73. PubMed ID: 25795305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
    Dardaei L; Wang HQ; Singh M; Fordjour P; Shaw KX; Yoda S; Kerr G; Yu K; Liang J; Cao Y; Chen Y; Lawrence MS; Langenbucher A; Gainor JF; Friboulet L; Dagogo-Jack I; Myers DT; Labrot E; Ruddy D; Parks M; Lee D; DiCecca RH; Moody S; Hao H; Mohseni M; LaMarche M; Williams J; Hoffmaster K; Caponigro G; Shaw AT; Hata AN; Benes CH; Li F; Engelman JA
    Nat Med; 2018 May; 24(4):512-517. PubMed ID: 29505033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
    Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
    J Pharmacol Exp Ther; 2014 Oct; 351(1):67-76. PubMed ID: 25073473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory Myofibroblastic Tumor Driven by Novel
    Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
    J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel PPP1CB-ALK fusion in spindle cell tumor defined by S100 and CD34 coexpression and distinctive stromal and perivascular hyalinization.
    Lopez-Nunez O; Surrey LF; Alaggio R; Fritchie KJ; John I
    Genes Chromosomes Cancer; 2020 Aug; 59(8):495-499. PubMed ID: 32222087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.
    Yun MR; Lim SM; Kim SK; Choi HM; Pyo KH; Kim SK; Lee JM; Lee YW; Choi JW; Kim HR; Hong MH; Haam K; Huh N; Kim JH; Kim YS; Shim HS; Soo RA; Shih JY; Yang JC; Kim M; Cho BC
    Cancer Res; 2018 Jun; 78(12):3350-3362. PubMed ID: 29669761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
    Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY
    Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma.
    Blandin AF; Giglio R; Graham MS; Garcia G; Malinowski S; Woods JK; Ramkissoon S; Ramkissoon L; Dubois F; Schoolcraft K; Tsai J; Wang D; Jones R; Vogelzang J; Pelton K; Becker S; Watkinson F; Sinai C; Cohen EF; Booker MA; Tolstorukov MY; Haemels V; Goumnerova L; Wright K; Kieran M; Fehnel K; Reardon D; Tauziede-Espariat A; Lulla R; Carcamo B; Chaleff S; Charest A; De Smet F; Ligon AH; Dubuc A; Pages M; Varlet P; Wen PY; Alexander BM; Chi S; Alexandrescu S; Kittler R; Bachoo R; Bandopadhayay P; Beroukhim R; Ligon KL
    Clin Cancer Res; 2023 Jul; 29(14):2651-2667. PubMed ID: 36780194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the Chernobyl accident.
    Arndt A; Steinestel K; Rump A; Sroya M; Bogdanova T; Kovgan L; Port M; Abend M; Eder S
    J Pathol Clin Res; 2018 Jul; 4(3):175-183. PubMed ID: 29633575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.